Changes in gut microbiome diversity are observed with certain antibiotic drugs years later, even after just one course of ...
SAN FRANCISCO — Luvesilocin, a novel psychedelic 5-hydroxytryptamine receptor 2A (5HT2A) agonist compound formerly known as RE104, was associated with fast and durable improvement in women with ...
The tragic death of a 41-year-old NASCAR champion from pneumonia and sepsis is a reminder that the conditions can strike at ...
UPV researchers created the FMB scale, a continuous index that ranks medications by driving risk more precisely than DRUID and could be integrated into e-prescribing tools.
New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results